Form 4: BioLife Solutions Executive Sells Shares Under Pre-Arranged Tax Plan
Insider Transaction Report
Karen A. Foster, Chief Quality and Operations at BioLife Solutions Inc., sold 400 shares of common stock for $22.27 per share on July 7, 2025, as part of a pre-arranged Rule 10b5-1 trading plan to cover tax obligations.
Summary
- Karen A. Foster, the Chief Quality and Operations Officer of BioLife Solutions Inc. (BLFS), reported a transaction involving the company's common stock.
- On July 7, 2025, Ms. Foster disposed of 400 shares of common stock.
- The shares were sold at a price of $22.27 per share.
- Following this transaction, Ms. Foster beneficially owns 194,596 shares of BioLife Solutions common stock.
- The sale was executed pursuant to a Rule 10b5-1(c) trading plan, which became effective on January 3, 2023.
- The purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock.
Sentiment
Score: 5
Explanation: The transaction is a routine, pre-planned sale for tax purposes by an executive, which is generally considered neutral in terms of company sentiment.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Management Comments
- The sale reported herein was made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Industry Context
This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information related to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in insider ownership, but its pre-planned, tax-related nature suggests it is not indicative of a change in management's confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 01-03-2023 | Effective date of the Rule 10b5-1(c) trading plan. |
| 07/07/2025 | Date of the reported transaction (sale of common stock). |
| 07/09/2025 | Date the Form 4 was signed and filed. |
Keywords
BioLife Solutions, BLFS, Form 4, Insider Trading, Stock Sale, Executive Compensation, 10b5-1 Plan, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.